Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 5, 2013, Pages 429-437

  Collier, Paul ^a   Patel, Keyur ^b   Waeltz, Paul ^a   Rupar, Mark ^a   Luthra, Rajyalakshmi ^b   Liu, Phillip C C ^a   Hollis, Gregory ^a   Huber, Reid ^a   Verstovsek, Srdan ^b   Burn, Timothy C ^a  

^a Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMINO ACID 617; JANUS KINASE 2; PHENYLALANINE; RUXOLITINIB; UNCLASSIFIED DRUG; VALINE;

ALLELE; ARTICLE; HUMAN; HUMAN CELL; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; PYROSEQUENCING; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; BONE MARROW NEOPLASMS; CELL LINE, TUMOR; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS;

EID: 84876950257     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0366     Document Type: Article

References (21)

1. Baxter EJ, Scott LM, Campbell PJ, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061.
2. Harrison C, Kiladjian JJ, Al-Ali HK, et al. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibro-sis. N Engl J Med 366:787-798.
3. Huijsmans CJ, Poodt J, Savelkoul PH, et al. (2011) Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide. J Mol Diagn 13:558-564.
4. Ihle JN, Gilliland DG (2007) Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 17:8-14.
5. James C, Delhommeau F, Marzac C, et al. (2006) Detection of JAK2 V617F as a first intention diagnostic test for ery-throcytosis. Leukemia 20:350-353.
6. James C, Ugo V, Le Couedic JP, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148.
7. Jelinek J, Oki Y, Gharibyan V, et al. (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and mega-karyocytic leukemia. Blood 106:3370-3373.
8. Jones AV, Kreil S, Zoi K, et al. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162-2168.
9. Kralovics R, Passamonti F, Buser AS, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790.
10. Levine RL, Belisle C, Wadleigh M, et al. (2006) X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal he-matopoiesis. Blood 107:4139-4141.
11. Levine RL, Wadleigh M, Cools J, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397.
12. Levine RL, Wernig G (2006) Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematol Am Soc Hematol Educ Program 233-239, 510.
13. Lippert E, Girodon F, Hammond E, et al. (2009) Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 94:38-45.
14. McClure R, Mai M, Lasho T (2006) Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 20:168-171.
15. Morishita S, Komatsu N, Kirito K, et al. (2011) Alternately binding probe competitive PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in myeloproliferative neoplasms. Leuk Res 35:1632-1636.
16. Olsen RJ, Tang Z, Farkas DH, et al. (2006) Detection of the JAK2V617F mutation in myeloproliferative disorders by melting curve analysis using the LightCycler System. Arch Pathol Lab Med 130:997-1003.
17. Quentmeier H, MacLeod RA, Zaborski M, et al. (2006) JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20:471-476.
18. Steensma DP (2006) JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 8:397-411; quiz 526.
19. Verstovsek S, Kantarjian H, Mesa RA, et al. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in mye-lofibrosis. N Engl J Med 363:1117-1127.
20. Verstovsek S, Mesa RA, Gotlib J, et al. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799-807.
21. Voelkner MH, Ben-Ezra J, West AC, et al. (2008) Performance evaluation of a commercially available quantitative allele specific real time PCR assay for the Janus kinase 2 V617F (JAK-2) mutation in chronic myeloproliferative disorders (CMD). J Mol Diagn 10:557-626; Abstract H525.